REGULATORY

MHLW Revises Conditions of Approval for Alecensa Based on Findings from Post-Marketing Survey

December 19, 2018
The Ministry of Health, Labor and Welfare (MHLW) has revised conditions of approval for Chugai Pharmaceutical’s non-small cell lung cancer (NSCLC) treatment Alecensa (alectinib) based on the analysis of post-marketing survey results and future plan to ensure proper use. In…

To read the full story

REGULATORY

By Takashi Ebisawa and Tatsuya Otsuka

Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

By Takashi Ebisawa

Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…

By Yoshinori Sagehashi

Japan positions its new cost-effectiveness assessment (CEA) scheme merely as a tool to complement the current drug pricing system, but…

Tatsuya Kondo, chief executive of the Pharmaceuticals and Medical Devices Agency (PMDA), is hitting the exit at the end of…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

By Reiji Anasako

With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…